CASI Pharmaceuticals, Inc.
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $5.0Mattributed |
|---|---|
| Latest round | Funding round, $5.0M, 2026-04-17attributed |
| Founded | 2023 |
| Headquarters | BEIJING, F4 |
| Industry | pharmaceuticals |
| Stage | unknown |
| Website | casipharmaceuticals.com |
CASI Pharmaceuticals is a biopharma company developing CID-103, a monoclonal antibody for organ transplant rejection and autoimmune conditions like immune thrombocytopenia. It targets transplant recipients and patients lacking adequate options on existing therapies. The anti-CD38 approach depletes plasma cells generating the harmful antibodies, addressing limitations seen with CD19 and CD20-targeted treatments.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-17 | Funding round | $5.0M | undisclosed |
Detected tech stack
Nginx, reCAPTCHA, jQuery Migrate, parallax.js, PHP, Duda production_6455, jquery 3., friendly-challenge 0.9.8
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $5.0M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $5.0M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | casipharmaceuticals.com, read 2026-05-07 |
| Description | self-reported | casipharmaceuticals.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $5.0M, 2026-04-17 → Funding round, $5.0M, 2026-04-17, sec-edgar, No document URL on file | Latest round | seed, $5.0M, 2026-04-17 → Funding round, $5.0M, 2026-04-17 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes